Elluru Sriramulu, Duong Van Huyen Jean-Paul, Prost Fabienne, Delignat Sandrine, Bayry Jagadeesh, Ephrem Amal, Siberil Sophie, Misra Namita, Lacroix-Desmzes Sebastien, Kazatchkine Michel D, Kaveri Srini V
INSERM U681, Université Pierre et Marie Curie, UPMC, Paris 6, Institut des Cordeliers, 15 Rue de l'Ecole de Médecine, 75006 Paris, France.
Immunol Lett. 2006 Sep 15;107(1):58-62. doi: 10.1016/j.imlet.2006.07.009. Epub 2006 Aug 22.
Intravenous immunoglobulin (IVIG) is increasingly used in the treatment of diverse immune-mediated disorders. Since several preparations of IVIG are available for therapy, it is possible that different manufacturing processes might influence clinical efficacy of IVIG. An insight into the mechanisms of action of such different IVIG preparations is therefore necessary that will provide further guidelines for the utility of IVIG preparations in autoimmune and inflammatory diseases. Since endothelial cells (EC) influence the inflammatory process via production of cytokines, chemokines and expression of adhesive molecules, we analyzed the anti-inflammatory effect on EC of two IVIG preparations: caprylated IVIG (IVIG-C) versus solvent/detergent-treated IVIG (IVIG-SD) preparation. We found that both IVIG preparations inhibit in an equivalent manner, the expression of different pro-inflammatory factors such as IL-6, IL-8, GM-CSF, IL-1beta and TNF-alpha and the adhesion molecules ICAM-1 and VCAM-1. Our results thus suggest that the caprylate while inactivating the virus and enhancing the yield of IgG during IVIG formulation, does not modulate the immunomodulatory properties of IVIG at EC level and that the two preparations show similar anti-inflammatory effects.
静脉注射免疫球蛋白（IVIG）越来越多地用于治疗各种免疫介导的疾病。由于有几种IVIG制剂可用于治疗，不同的生产工艺可能会影响IVIG的临床疗效。因此，有必要深入了解这些不同IVIG制剂的作用机制，这将为IVIG制剂在自身免疫性疾病和炎症性疾病中的应用提供进一步的指导方针。由于内皮细胞（EC）通过产生细胞因子、趋化因子和表达黏附分子来影响炎症过程，我们分析了两种IVIG制剂对EC的抗炎作用：辛酰化IVIG（IVIG-C）与溶剂/去污剂处理的IVIG（IVIG-SD）制剂。我们发现，两种IVIG制剂以同等方式抑制不同促炎因子如IL-6、IL-8、GM-CSF、IL-1β和TNF-α以及黏附分子ICAM-1和VCAM-1的表达。因此，我们的结果表明，辛酸盐在使病毒失活并提高IVIG制剂中IgG产量的同时，不会在EC水平调节IVIG的免疫调节特性，并且这两种制剂显示出相似的抗炎作用。
